t-butyl 4-{4-[(3-fluorobenzyl)oxy]phenoxy}piperidine-1-carboxylate | 847156-32-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: t-butyl 4-{4-[(3-fluorobenzyl)oxy]phenoxy}piperidine-1-carboxylate
• 英文别名: tert-butyl 4-{4-[(3-fluorobenzyl)oxy]phenoxy}piperidine-1-carboxylate；Tert-butyl 4-[4-(3-fluorobenzyloxy)phenoxy]piperidine-1-carboxylate；tert-butyl 4-[4-[(3-fluorophenyl)methoxy]phenoxy]piperidine-1-carboxylate
• CAS: 847156-32-5
• 化学式: C₂₃H₂₈FNO₄
• 分子量: 401.478
• InChiKey: XLVPKUDANMXGKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  t-butyl 4-{4-[(3-fluorobenzyl)oxy]phenoxy}piperidine-1-carboxylate 在 盐酸 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 为溶剂， 反应 0.5h， 生成 methyl 4-{4-[(3-fluorobenzyl)oxy]phenoxy}piperidine-1-carboxylate
  参考文献：
  名称：

  Synthesis and structure–activity relationships of benzyloxyphenyl derivatives as a novel class of NCX inhibitors: effects on heart failure

  摘要：

  In the context of heart failure and myocardial ischemia reperfusion, the activity of the sodium-calcium exchanger can lead to calcium overload, which in turn can lead to contractile dysfunction and arrhythmia. Therefore, NCX is an attractive target for treatment of heart failure and myocardial ischemia reperfusion. We have designed and synthesized a series of benzyloxyphenyl derivatives as potential NCX inhibitors, based on compound 4. These derivatives have been evaluated for their inhibitory activity against both the reverse and forward modes of NCX, and two novel potent NCX inhibitors (7i, 10a) were discovered. Compound 7i was evaluated for its efficacy on ouabain-induced tonotropy and arrhythmia in a heart-failure model. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.10.048
• 作为产物：
  描述：

  tert-butyl 4-(4-hydroxyphenoxy)piperidine-1-carboxylate 、 3-氟溴苄 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 22.0h， 生成 t-butyl 4-{4-[(3-fluorobenzyl)oxy]phenoxy}piperidine-1-carboxylate
  参考文献：
  名称：

  Piperazine derivatives for the treatment of urinary incontinence and pain

  摘要：

  公开号：

  EP1849773B1

文献信息

• UREA COMPOUND OR SALT THEREOF
  申请人：Ishii Takahiro

  公开号：US20110172230A1

  公开（公告）日：2011-07-14

  [Object] To provide a compound which can be used for the treatment of a disease associated with fatty acid amide hydrolase (FAAH), particularly urinary frequency, urinary incontinence and/or overactive bladder. [Means for solution] It is confirmed that a urea compound chemical-structurally characterized by having a piperidine or piperazine ring or a salt thereof has an excellent FAAH-inhibitory activity, and thus the present invention is completed. The urea compound or its pharmaceutically acceptable salt of the present invention can increase the effective bladder capacity and ameliorate the state of urinary frequency, and is therefore useful as an agent for treating urinary frequency, urinary incontinence and/or overactive bladder.

  [目的] 提供一种化合物，可用于治疗与脂肪酸酰胺水解酶（FAAH）相关的疾病，特别是尿频、尿失禁和/或膀胱过度活动。 [解决方案] 确认具有哌啶或哌嗪环或其盐的尿素化合物在化学结构上具有出色的FAAH抑制活性，因此完成了本发明。本发明的尿素化合物或其药学上可接受的盐可以增加有效膀胱容量，改善尿频状态，因此可用作治疗尿频、尿失禁和/或膀胱过度活动的药物。
• Synthesis and structure–activity relationships of benzyloxyphenyl derivatives as a novel class of NCX inhibitors: effects on heart failure
  作者：Takahiro Kuramochi、Akio Kakefuda、Hiroyoshi Yamada、Takashi Ogiyama、Taku Taguchi、Shuichi Sakamoto

  DOI：10.1016/j.bmc.2004.10.048

  日期：2005.2

  In the context of heart failure and myocardial ischemia reperfusion, the activity of the sodium-calcium exchanger can lead to calcium overload, which in turn can lead to contractile dysfunction and arrhythmia. Therefore, NCX is an attractive target for treatment of heart failure and myocardial ischemia reperfusion. We have designed and synthesized a series of benzyloxyphenyl derivatives as potential NCX inhibitors, based on compound 4. These derivatives have been evaluated for their inhibitory activity against both the reverse and forward modes of NCX, and two novel potent NCX inhibitors (7i, 10a) were discovered. Compound 7i was evaluated for its efficacy on ouabain-induced tonotropy and arrhythmia in a heart-failure model. (C) 2004 Elsevier Ltd. All rights reserved.
• Piperazine derivatives for the treatment of urinary incontinence and pain
  申请人：Astellas Pharma Inc.

  公开号：EP1849773B1

  公开（公告）日：2013-10-16